+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
NDDS in Cancer Therapy Market - Global Forecast 2026-2032- Product Image
NDDS in Cancer Therapy Market - Global Forecast 2026-2032- Product Image
Sale

NDDS in Cancer Therapy Market - Global Forecast 2026-2032

  • Report

  • 183 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 5888824
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The NDDS in Cancer Therapy Market is projected to reach USD 20.37 Billion in 2026. It is expected to continue growing at a CAGR of 16.23%, reaching USD 50.47 Billion by 2032.

Introduction to Novel Drug Delivery Systems in Cancer Therapy

Novel drug delivery systems (NDDS) in cancer therapy use formulation, material, and device innovations to improve how anticancer agents reach tumors and affect healthy tissue. Relevant approaches include nanoparticles, liposomes, polymeric carriers, antibody-drug conjugate platforms, implantable systems, and stimuli-responsive delivery. Their clinical value is assessed through pharmacokinetic control, tumor targeting, tolerability, manufacturability, regulatory readiness, and compatibility with established treatment pathways.

Transformative Shifts Reshaping Cancer Drug Delivery

The field is shifting from conventional systemic administration toward delivery designs that address tumor heterogeneity, biological barriers, and dose-limiting toxicity. Greater attention is being placed on site-specific release, combination regimens, immune-system interactions, patient selection, and scalable production. Progress is also shaped by stricter expectations for characterization, comparability, long-term safety, and evidence that delivery improvements translate into meaningful clinical benefit.

How Artificial Intelligence Is Accelerating Delivery Innovation

Artificial intelligence can support NDDS development by analyzing molecular, formulation, imaging, and clinical datasets to identify delivery candidates and predict drug-carrier interactions. Machine learning may also assist with particle-size optimization, release-profile design, toxicity screening, patient stratification, and manufacturing-process monitoring. Its contribution depends on representative data, transparent validation, regulatory-quality documentation, and human oversight, particularly when models influence clinical or production decisions.

Regional Insights Across North America, Latin America, Europe, the Middle East, Africa, and Asia-Pacific

North America emphasizes translational research, advanced biologics infrastructure, and regulatory pathways for complex delivery platforms. Europe combines strong academic networks with coordinated regulatory and health-technology assessment requirements. Asia-Pacific is characterized by expanding biopharmaceutical capabilities, substantial oncology demand, and varied access conditions across Australia, China, India, Japan, and South Korea. Latin America is shaped by uneven diagnostic and treatment access, local manufacturing priorities, and health-system affordability. The Middle East is investing selectively in specialized care and research capacity, while Africa’s priorities include reliable supply, adaptable delivery technologies, and stronger oncology infrastructure.

Group Insights Across ASEAN, BRICS, the European Union, G7, GCC, and NATO

ASEAN markets present diverse regulatory systems and healthcare capacity, making regional harmonization and temperature-resilient distribution important considerations. BRICS members combine large patient populations with varying research, manufacturing, and access capabilities, supporting interest in locally adaptable platforms. The European Union benefits from regulatory coordination but must address evidence consistency and reimbursement variation. G7 countries generally have mature clinical and manufacturing ecosystems, while GCC states are strengthening specialized healthcare and procurement capabilities. NATO members span different health systems, but shared emphasis on supply-chain resilience, biomedical security, and advanced research can influence delivery-system adoption.

Country Insights for Fifteen Priority Markets

Australia supports oncology research through established clinical institutions and a regulated healthcare environment. Brazil and Mexico face access and infrastructure variation while developing local capabilities. Canada and the United States combine advanced research, specialized care, and rigorous evidence requirements. China and India are expanding pharmaceutical and manufacturing capacity amid substantial clinical need. France, Germany, Italy, Spain, and the United Kingdom emphasize clinical evidence, regulatory compliance, and health-system value, with differences in reimbursement and procurement. Japan is recognized for sophisticated pharmaceutical development and quality requirements. South Korea is strengthening biologics, precision-medicine, and advanced manufacturing capabilities. Russia’s environment is influenced by domestic production priorities, regulatory conditions, and supply-chain constraints.

Actionable Priorities for NDDS Industry Leaders

Leaders should prioritize delivery platforms with a clearly defined clinical problem, measurable pharmacologic advantage, and manufacturable design. Development plans should integrate early regulatory consultation, robust characterization, scalable processes, and comparability strategies for formulation or production changes. Partnerships with oncology centers can improve patient-selection methods and real-world evidence, while collaboration with diagnostic developers may strengthen biomarker-guided delivery. Organizations should also assess cold-chain dependence, raw-material security, regional reimbursement requirements, cybersecurity, and responsible use of artificial intelligence before committing to broad commercialization programs.

Research Methodology for the Executive Summary

This summary applies a structured qualitative review of NDDS applications in cancer therapy, organized by technology, clinical objective, development stage, geography, and healthcare-system context. Evidence should be triangulated using peer-reviewed research, clinical-trial records, regulatory publications, pharmacovigilance information, scientific congress materials, and authoritative public-health sources. Findings are interpreted comparatively rather than as market measurement, with attention to evidence quality, reproducibility, regulatory status, manufacturing feasibility, access conditions, and limitations in available data.

Conclusion: Building Clinically Useful and Scalable Cancer Delivery Systems

NDDS innovation is increasingly defined by the ability to solve specific therapeutic and operational problems rather than by novelty alone. The strongest opportunities are likely to combine validated targeting or release mechanisms with dependable manufacturing, clinically relevant endpoints, and equitable delivery across different health systems. Sustained progress will require interdisciplinary development, disciplined evidence generation, regional regulatory awareness, and careful governance of artificial intelligence throughout discovery, production, and patient care.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. NDDS in Cancer Therapy Market, by Product Type
7.1. Introduction
7.2. Dendrimers
7.3. Exosomes
7.4. Lipid Nanocarriers
7.5. Liposomes
7.6. Metallic Nanoparticles
7.7. Micelles
7.8. Nanoemulsions
7.9. Polymeric Nanoparticles
8. NDDS in Cancer Therapy Market, by Drug Type
8.1. Introduction
8.2. Gene Therapy Agents
8.3. Monoclonal Antibodies
8.4. Oligonucleotide Drugs
8.5. SiRNA
8.6. Small-Molecule Chemotherapeutics
9. NDDS in Cancer Therapy Market, by Technology Platform
9.1. Introduction
9.2. Implantable Depot Systems
9.3. Injectable Suspensions
9.4. Microneedle Systems
9.5. Nanotechnology
10. NDDS in Cancer Therapy Market, by Application
10.1. Introduction
10.2. Chemotherapy
10.3. Immunotherapy
10.4. Photodynamic Therapy
10.5. Radiotherapy
10.6. Targeted Therapy
11. NDDS in Cancer Therapy Market, by Region
11.1. Introduction
11.2. Asia-Pacific
11.3. Europe
11.4. North America
11.5. Latin America
11.6. Africa
11.7. Middle East
12. NDDS in Cancer Therapy Market, by Group
12.1. Introduction
12.2. NATO
12.3. G7
12.4. BRICS
12.5. European Union
12.6. ASEAN
12.7. GCC
13. NDDS in Cancer Therapy Market, by Country
13.1. Introduction
13.2. China
13.3. United States
13.4. Japan
13.5. India
13.6. Germany
13.7. United Kingdom
13.8. Australia
13.9. France
13.10. South Korea
13.11. Italy
13.12. Canada
13.13. Russia
13.14. Brazil
13.15. Mexico
13.16. Spain
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. Market Concentration Analysis, 2025
14.2.1. Concentration Ratio (CR)
14.2.2. Herfindahl Hirschman Index (HHI)
14.3. Recent Developments & Impact Analysis, 2025
14.4. Product Portfolio Analysis, 2025
14.5. Benchmarking Analysis, 2025
15. Company Profiles
15.1. Abbott Laboratories
15.2. AbbVie Inc.
15.3. AstraZeneca PLC
15.4. Bayer AG
15.5. Boston Scientific Corporation
15.6. Bristol Myers Squibb Company
15.7. Cospheric LLC
15.8. Eli Lilly and Company
15.9. Enable Injections, Inc.
15.10. Evonik Industries AG
15.11. F. Hoffmann-La Roche Ltd.
15.12. GSK plc
15.13. Ipsen S.A.
15.14. Johnson & Johnson
15.15. Merck & Co., Inc.
15.16. Merit Medical Systems, Inc.
15.17. MO-SCI Corporation
15.18. Nanobiotix S.A.
15.19. Novartis AG
15.20. Pacira BioSciences, Inc.
15.21. Pfizer Inc.
15.22. Samyang Holdings Corporation
15.23. Sanofi
15.24. Teva Pharmaceutical Industries Ltd.
15.25. West Pharmaceutical Services, Inc.
16. Key Experts
LIST OF FIGURES
FIGURE 1. Global NDDS in Cancer Therapy Market, Years Considered for the Study
FIGURE 2. Global NDDS in Cancer Therapy Market, Research Design
FIGURE 3. Global NDDS in Cancer Therapy Market, Research Framework
FIGURE 4. Global NDDS in Cancer Therapy Market, Data Triangulation
FIGURE 5. Global NDDS in Cancer Therapy Market Size, 2017-2032 (USD Million)
FIGURE 6. Global NDDS in Cancer Therapy Market Size, by Product Type, 2025 vs 2032 (%)
FIGURE 7. Global NDDS in Cancer Therapy Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global NDDS in Cancer Therapy Market Size, by Drug Type, 2025 vs 2032 (%)
FIGURE 9. Global NDDS in Cancer Therapy Market Size, by Drug Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global NDDS in Cancer Therapy Market Size, by Technology Platform, 2025 vs 2032 (%)
FIGURE 11. Global NDDS in Cancer Therapy Market Size, by Technology Platform, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global NDDS in Cancer Therapy Market Size, by Application, 2025 vs 2032 (%)
FIGURE 13. Global NDDS in Cancer Therapy Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global NDDS in Cancer Therapy Market Size, by Region, 2025 vs 2032 (%)
FIGURE 15. Global NDDS in Cancer Therapy Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global NDDS in Cancer Therapy Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 17. Global NDDS in Cancer Therapy Market Size, by Country, 2025 vs 2032 (%)
FIGURE 18. Global NDDS in Cancer Therapy Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global NDDS in Cancer Therapy Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global NDDS in Cancer Therapy Market Segmentation & Coverage
TABLE 2. Global NDDS in Cancer Therapy Market Size, 2017-2032 (USD Million)
TABLE 3. Global NDDS in Cancer Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 4. Global Dendrimers Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Dendrimers Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Dendrimers Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Exosomes Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Exosomes Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Exosomes Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Lipid Nanocarriers Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Lipid Nanocarriers Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Lipid Nanocarriers Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Liposomes Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Liposomes Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Liposomes Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Metallic Nanoparticles Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Metallic Nanoparticles Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Metallic Nanoparticles Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Micelles Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Micelles Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Micelles Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Nanoemulsions Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Nanoemulsions Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Nanoemulsions Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Polymeric Nanoparticles Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Polymeric Nanoparticles Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Polymeric Nanoparticles Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global NDDS in Cancer Therapy Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 29. Global Gene Therapy Agents Market Size, by Region, 2017-2032 (USD Million)
TABLE 30. Global Gene Therapy Agents Market Size, by Group, 2017-2032 (USD Million)
TABLE 31. Global Gene Therapy Agents Market Size, by Country, 2017-2032 (USD Million)
TABLE 32. Global Monoclonal Antibodies Market Size, by Region, 2017-2032 (USD Million)
TABLE 33. Global Monoclonal Antibodies Market Size, by Group, 2017-2032 (USD Million)
TABLE 34. Global Monoclonal Antibodies Market Size, by Country, 2017-2032 (USD Million)
TABLE 35. Global Oligonucleotide Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global Oligonucleotide Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global Oligonucleotide Drugs Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global SiRNA Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global SiRNA Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global SiRNA Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Small-Molecule Chemotherapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Small-Molecule Chemotherapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Small-Molecule Chemotherapeutics Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global NDDS in Cancer Therapy Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 45. Global Implantable Depot Systems Market Size, by Region, 2017-2032 (USD Million)
TABLE 46. Global Implantable Depot Systems Market Size, by Group, 2017-2032 (USD Million)
TABLE 47. Global Implantable Depot Systems Market Size, by Country, 2017-2032 (USD Million)
TABLE 48. Global Injectable Suspensions Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Global Injectable Suspensions Market Size, by Group, 2017-2032 (USD Million)
TABLE 50. Global Injectable Suspensions Market Size, by Country, 2017-2032 (USD Million)
TABLE 51. Global Microneedle Systems Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Microneedle Systems Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Microneedle Systems Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global Nanotechnology Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Global Nanotechnology Market Size, by Group, 2017-2032 (USD Million)
TABLE 56. Global Nanotechnology Market Size, by Country, 2017-2032 (USD Million)
TABLE 57. Global NDDS in Cancer Therapy Market Size, by Application, 2017-2032 (USD Million)
TABLE 58. Global Chemotherapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 59. Global Chemotherapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 60. Global Chemotherapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 61. Global Immunotherapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Global Immunotherapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 63. Global Immunotherapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 64. Global Photodynamic Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Global Photodynamic Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 66. Global Photodynamic Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 67. Global Radiotherapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 68. Global Radiotherapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 69. Global Radiotherapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 70. Global Targeted Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 71. Global Targeted Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 72. Global Targeted Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 73. Global NDDS in Cancer Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 74. Asia-Pacific NDDS in Cancer Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 75. Asia-Pacific NDDS in Cancer Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 76. Asia-Pacific NDDS in Cancer Therapy Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 77. Asia-Pacific NDDS in Cancer Therapy Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 78. Asia-Pacific NDDS in Cancer Therapy Market Size, by Application, 2017-2032 (USD Million)
TABLE 79. Europe NDDS in Cancer Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 80. Europe NDDS in Cancer Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 81. Europe NDDS in Cancer Therapy Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 82. Europe NDDS in Cancer Therapy Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 83. Europe NDDS in Cancer Therapy Market Size, by Application, 2017-2032 (USD Million)
TABLE 84. North America NDDS in Cancer Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 85. North America NDDS in Cancer Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 86. North America NDDS in Cancer Therapy Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 87. North America NDDS in Cancer Therapy Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 88. North America NDDS in Cancer Therapy Market Size, by Application, 2017-2032 (USD Million)
TABLE 89. Latin America NDDS in Cancer Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 90. Latin America NDDS in Cancer Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 91. Latin America NDDS in Cancer Therapy Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 92. Latin America NDDS in Cancer Therapy Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 93. Latin America NDDS in Cancer Therapy Market Size, by Application, 2017-2032 (USD Million)
TABLE 94. Africa NDDS in Cancer Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 95. Africa NDDS in Cancer Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 96. Africa NDDS in Cancer Therapy Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 97. Africa NDDS in Cancer Therapy Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 98. Africa NDDS in Cancer Therapy Market Size, by Application, 2017-2032 (USD Million)
TABLE 99. Middle East NDDS in Cancer Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 100. Middle East NDDS in Cancer Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 101. Middle East NDDS in Cancer Therapy Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 102. Middle East NDDS in Cancer Therapy Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 103. Middle East NDDS in Cancer Therapy Market Size, by Application, 2017-2032 (USD Million)
TABLE 104. Global NDDS in Cancer Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 105. NATO NDDS in Cancer Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 106. NATO NDDS in Cancer Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 107. NATO NDDS in Cancer Therapy Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 108. NATO NDDS in Cancer Therapy Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 109. NATO NDDS in Cancer Therapy Market Size, by Application, 2017-2032 (USD Million)
TABLE 110. G7 NDDS in Cancer Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 111. G7 NDDS in Cancer Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 112. G7 NDDS in Cancer Therapy Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 113. G7 NDDS in Cancer Therapy Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 114. G7 NDDS in Cancer Therapy Market Size, by Application, 2017-2032 (USD Million)
TABLE 115. BRICS NDDS in Cancer Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 116. BRICS NDDS in Cancer Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 117. BRICS NDDS in Cancer Therapy Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 118. BRICS NDDS in Cancer Therapy Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 119. BRICS NDDS in Cancer Therapy Market Size, by Application, 2017-2032 (USD Million)
TABLE 120. European Union NDDS in Cancer Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 121. European Union NDDS in Cancer Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 122. European Union NDDS in Cancer Therapy Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 123. European Union NDDS in Cancer Therapy Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 124. European Union NDDS in Cancer Therapy Market Size, by Application, 2017-2032 (USD Million)
TABLE 125. ASEAN NDDS in Cancer Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 126. ASEAN NDDS in Cancer Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 127. ASEAN NDDS in Cancer Therapy Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 128. ASEAN NDDS in Cancer Therapy Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 129. ASEAN NDDS in Cancer Therapy Market Size, by Application, 2017-2032 (USD Million)
TABLE 130. GCC NDDS in Cancer Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 131. GCC NDDS in Cancer Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 132. GCC NDDS in Cancer Therapy Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 133. GCC NDDS in Cancer Therapy Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 134. GCC NDDS in Cancer Therapy Market Size, by Application, 2017-2032 (USD Million)
TABLE 135. Global NDDS in Cancer Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 136. China NDDS in Cancer Therapy Market Size, 2017-2032 (USD Million)
TABLE 137. China NDDS in Cancer Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 138. China NDDS in Cancer Therapy Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 139. China NDDS in Cancer Therapy Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 140. China NDDS in Cancer Therapy Market Size, by Application, 2017-2032 (USD Million)
TABLE 141. United States NDDS in Cancer Therapy Market Size, 2017-2032 (USD Million)
TABLE 142. United States NDDS in Cancer Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 143. United States NDDS in Cancer Therapy Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 144. United States NDDS in Cancer Therapy Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 145. United States NDDS in Cancer Therapy Market Size, by Application, 2017-2032 (USD Million)
TABLE 146. Japan NDDS in Cancer Therapy Market Size, 2017-2032 (USD Million)
TABLE 147. Japan NDDS in Cancer Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 148. Japan NDDS in Cancer Therapy Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 149. Japan NDDS in Cancer Therapy Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 150. Japan NDDS in Cancer Therapy Market Size, by Application, 2017-2032 (USD Million)
TABLE 151. India NDDS in Cancer Therapy Market Size, 2017-2032 (USD Million)
TABLE 152. India NDDS in Cancer Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 153. India NDDS in Cancer Therapy Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 154. India NDDS in Cancer Therapy Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 155. India NDDS in Cancer Therapy Market Size, by Application, 2017-2032 (USD Million)
TABLE 156. Germany NDDS in Cancer Therapy Market Size, 2017-2032 (USD Million)
TABLE 157. Germany NDDS in Cancer Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 158. Germany NDDS in Cancer Therapy Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 159. Germany NDDS in Cancer Therapy Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 160. Germany NDDS in Cancer Therapy Market Size, by Application, 2017-2032 (USD Million)
TABLE 161. United Kingdom NDDS in Cancer Therapy Market Size, 2017-2032 (USD Million)
TABLE 162. United Kingdom NDDS in Cancer Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 163. United Kingdom NDDS in Cancer Therapy Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 164. United Kingdom NDDS in Cancer Therapy Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 165. United Kingdom NDDS in Cancer Therapy Market Size, by Application, 2017-2032 (USD Million)
TABLE 166. Australia NDDS in Cancer Therapy Market Size, 2017-2032 (USD Million)
TABLE 167. Australia NDDS in Cancer Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 168. Australia NDDS in Cancer Therapy Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 169. Australia NDDS in Cancer Therapy Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 170. Australia NDDS in Cancer Therapy Market Size, by Application, 2017-2032 (USD Million)
TABLE 171. France NDDS in Cancer Therapy Market Size, 2017-2032 (USD Million)
TABLE 172. France NDDS in Cancer Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 173. France NDDS in Cancer Therapy Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 174. France NDDS in Cancer Therapy Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 175. France NDDS in Cancer Therapy Market Size, by Application, 2017-2032 (USD Million)
TABLE 176. South Korea NDDS in Cancer Therapy Market Size, 2017-2032 (USD Million)
TABLE 177. South Korea NDDS in Cancer Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 178. South Korea NDDS in Cancer Therapy Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 179. South Korea NDDS in Cancer Therapy Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 180. South Korea NDDS in Cancer Therapy Market Size, by Application, 2017-2032 (USD Million)
TABLE 181. Italy NDDS in Cancer Therapy Market Size, 2017-2032 (USD Million)
TABLE 182. Italy NDDS in Cancer Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 183. Italy NDDS in Cancer Therapy Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 184. Italy NDDS in Cancer Therapy Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 185. Italy NDDS in Cancer Therapy Market Size, by Application, 2017-2032 (USD Million)
TABLE 186. Canada NDDS in Cancer Therapy Market Size, 2017-2032 (USD Million)
TABLE 187. Canada NDDS in Cancer Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 188. Canada NDDS in Cancer Therapy Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 189. Canada NDDS in Cancer Therapy Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 190. Canada NDDS in Cancer Therapy Market Size, by Application, 2017-2032 (USD Million)
TABLE 191. Russia NDDS in Cancer Therapy Market Size, 2017-2032 (USD Million)
TABLE 192. Russia NDDS in Cancer Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 193. Russia NDDS in Cancer Therapy Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 194. Russia NDDS in Cancer Therapy Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 195. Russia NDDS in Cancer Therapy Market Size, by Application, 2017-2032 (USD Million)
TABLE 196. Brazil NDDS in Cancer Therapy Market Size, 2017-2032 (USD Million)
TABLE 197. Brazil NDDS in Cancer Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 198. Brazil NDDS in Cancer Therapy Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 199. Brazil NDDS in Cancer Therapy Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 200. Brazil NDDS in Cancer Therapy Market Size, by Application, 2017-2032 (USD Million)
TABLE 201. Mexico NDDS in Cancer Therapy Market Size, 2017-2032 (USD Million)
TABLE 202. Mexico NDDS in Cancer Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 203. Mexico NDDS in Cancer Therapy Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 204. Mexico NDDS in Cancer Therapy Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 205. Mexico NDDS in Cancer Therapy Market Size, by Application, 2017-2032 (USD Million)
TABLE 206. Spain NDDS in Cancer Therapy Market Size, 2017-2032 (USD Million)
TABLE 207. Spain NDDS in Cancer Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 208. Spain NDDS in Cancer Therapy Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 209. Spain NDDS in Cancer Therapy Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 210. Spain NDDS in Cancer Therapy Market Size, by Application, 2017-2032 (USD Million)
TABLE 211. Global NDDS in Cancer Therapy Market Share, by Key Player, 2025
TABLE 212. Global NDDS in Cancer Therapy Market, Key Experts

Companies Mentioned

  • Abbott Laboratories
  • AbbVie Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boston Scientific Corporation
  • Bristol Myers Squibb Company
  • Cospheric LLC
  • Eli Lilly and Company
  • Enable Injections, Inc.
  • Evonik Industries AG
  • F. Hoffmann-La Roche Ltd.
  • GSK plc
  • Ipsen S.A.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Merit Medical Systems, Inc.
  • MO-SCI Corporation
  • Nanobiotix S.A.
  • Novartis AG
  • Pacira BioSciences, Inc.
  • Pfizer Inc.
  • Samyang Holdings Corporation
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • West Pharmaceutical Services, Inc.

Related Topics

Related Reports

NDDS in Cancer Therapy - Global Strategic Business Report - Product Image

NDDS in Cancer Therapy - Global Strategic Business Report

  • Report
  • 130 Pages
  • Global
From
Novel Drug Delivery Systems in Cancer Therapy - Global Strategic Business Report - Product Image

Novel Drug Delivery Systems in Cancer Therapy - Global Strategic Business Report

  • Report
  • 181 Pages
  • Global
From
Cancer Drugs Market - Global Forecast 2026-2032 - Product Image

Cancer Drugs Market - Global Forecast 2026-2032

  • Report
  • 191 Pages
  • Global
From
Cancer Biological Therapy Market - Global Forecast 2026-2032 - Product Image

Cancer Biological Therapy Market - Global Forecast 2026-2032

  • Report
  • 196 Pages
  • Global
From
Oncolytic Virus Immunotherapy Market Opportunity, Technology Platforms, Approved Therapy Dosage, Price & Clinical Trials Insight 2031 - Product Image

Oncolytic Virus Immunotherapy Market Opportunity, Technology Platforms, Approved Therapy Dosage, Price & Clinical Trials Insight 2031

  • Report
  • 410 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.